139 related articles for article (PubMed ID: 37652507)
1. Plasma Circulating Cell-free DNA in Advanced Hepatocellular Carcinoma Patients Treated With Radiation Therapy.
Kim DY; Cho EH; Kim JS; Chie EK; Kang HC
In Vivo; 2023; 37(5):2306-2313. PubMed ID: 37652507
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
3. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.
Wang Y; Zhou K; Wang X; Liu Y; Guo D; Bian Z; Su L; Liu K; Gu X; Guo X; Wang L; Zhang H; Tao K; Xing J
Cancer Sci; 2021 Nov; 112(11):4772-4784. PubMed ID: 34490703
[TBL] [Abstract][Full Text] [Related]
4. Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma.
Park S; Lee EJ; Rim CH; Seong J
Yonsei Med J; 2018 Jun; 59(4):470-479. PubMed ID: 29749129
[TBL] [Abstract][Full Text] [Related]
5. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
[TBL] [Abstract][Full Text] [Related]
6. Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma.
Dong X; Chen G; Huang X; Li Z; Peng F; Chen H; Zhou Y; He L; Qiu L; Cai Z; Liu J; Liu X
Mol Oncol; 2022 May; 16(10):1986-1999. PubMed ID: 34939323
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma.
Yan L; Chen Y; Zhou J; Zhao H; Zhang H; Wang G
Int J Infect Dis; 2018 Feb; 67():92-97. PubMed ID: 29229500
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and survival impact of BCL9 and RPS6KB1 copy number variation detected from circulating free DNA in hepatocellular carcinoma.
Youssef SS; El-Araby RE; Abbas EAE; Hassany M; Elbaz T
Expert Rev Mol Diagn; 2023 Mar; 23(3):267-278. PubMed ID: 36803362
[TBL] [Abstract][Full Text] [Related]
9. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
10. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma.
Coto-Llerena M; Benjak A; Gallon J; Meier MA; Boldanova T; Terracciano LM; Ng CKY; Piscuoglio S
JCO Precis Oncol; 2022 Mar; 6():e2100335. PubMed ID: 35263170
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA.
Hlady RA; Zhao X; Pan X; Yang JD; Ahmed F; Antwi SO; Giama NH; Patel T; Roberts LR; Liu C; Robertson KD
Theranostics; 2019; 9(24):7239-7250. PubMed ID: 31695765
[TBL] [Abstract][Full Text] [Related]
13. Hypomethylation in HBV integration regions aids non-invasive surveillance to hepatocellular carcinoma by low-pass genome-wide bisulfite sequencing.
Zhang H; Dong P; Guo S; Tao C; Chen W; Zhao W; Wang J; Cheung R; Villanueva A; Fan J; Ding H; Schrodi SJ; Zhang D; Zeng C
BMC Med; 2020 Aug; 18(1):200. PubMed ID: 32741373
[TBL] [Abstract][Full Text] [Related]
14. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
[TBL] [Abstract][Full Text] [Related]
15. Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers.
Yang X; Hu Y; Yang K; Wang D; Lin J; Long J; Xie F; Mao J; Bian J; Guan M; Pan J; Huo L; Hu K; Yang X; Mao Y; Sang X; Zhang J; Wang X; Zhang H; Zhao H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972389
[TBL] [Abstract][Full Text] [Related]
16. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma.
Elzehery R; Effat N; El Farahaty R; Elsayed Farag R; Abo-Hashem EM; Elhelaly R
Am J Clin Pathol; 2022 Aug; 158(2):254-262. PubMed ID: 35403666
[TBL] [Abstract][Full Text] [Related]
17. Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Song S; Bai M; Li X; Gong S; Yang W; Lei C; Tian H; Si M; Hao X; Guo T
Expert Rev Mol Diagn; 2022 Mar; 22(3):361-378. PubMed ID: 35234564
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma.
Long G; Fang T; Su W; Mi X; Zhou L
Scand J Gastroenterol; 2020 Dec; 55(12):1441-1446. PubMed ID: 33119422
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive DNA methylation analysis of tissue of origin of plasma cell-free DNA by methylated CpG tandem amplification and sequencing (MCTA-Seq).
Liu X; Ren J; Luo N; Guo H; Zheng Y; Li J; Tang F; Wen L; Peng J
Clin Epigenetics; 2019 Jun; 11(1):93. PubMed ID: 31234922
[TBL] [Abstract][Full Text] [Related]
20. Liquid biopsy by combining 5-hydroxymethylcytosine signatures of plasma cell-free DNA and protein biomarkers for diagnosis and prognosis of hepatocellular carcinoma.
Cai Z; Zhang J; He Y; Xia L; Dong X; Chen G; Zhou Y; Hu X; Zhong S; Wang Y; Chen H; Xie D; Liu X; Liu J
ESMO Open; 2021 Feb; 6(1):100021. PubMed ID: 33508734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
